Avadel Pharmaceuticals 미래 성장

Future 기준 확인 6/6

Avadel Pharmaceuticals (는) 각각 연간 64.2% 및 29.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 64.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 141.5% 로 예상됩니다.

주요 정보

64.2%

수익 성장률

64.6%

EPS 성장률

Pharmaceuticals 수익 성장	24.1%
매출 성장률	29.1%
향후 자기자본 수익률	141.5%
애널리스트 커버리지	Good
마지막 업데이트	03 Dec 2024

최근 미래 성장 업데이트

Recent updates

The Price Is Right For Avadel Pharmaceuticals plc (NASDAQ:AVDL) Even After Diving 27%

Dec 01

Avadel Pharmaceuticals: Despite My Sympathies For The Company, Stock Looks Risky

Nov 22

Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?

May 03

Avadel Pharmaceuticals filed for 500M mixed shelf offering

Aug 31

Avadel Pharmaceuticals Q2 2022 Earnings Preview

Aug 08

Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt

Jul 07

Avadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023

Jun 29

Avadel: Further Delay, But Some Light At The End Of The Tunnel

Jun 16

Avadel Pharmaceuticals Plc: Initiating Buy, Bye Bye To Sleepiness

Mar 21

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Mar 15

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Nov 19

Avadel Pharmaceuticals: I Am Holding

Nov 01

Avadel Pharmaceuticals, The Jazz-Killer

Aug 05

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt In A Risky Way?

Jul 23

Avadel presents new clinical data from Phase 3 REST-ON trial of FT218 in narcolepsy

Jun 09

Avadel Pharmaceuticals EPS beats by $0.09

May 10

Need To Know: The Consensus Just Cut Its Avadel Pharmaceuticals plc (NASDAQ:AVDL) Estimates For 2021

Mar 11

수익 및 매출 성장 예측

NasdaqGM:AVDL - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	390	129	91	127	6
12/31/2025	291	48	32	42	8
12/31/2024	171	-48	20	-32	8
9/30/2024	138	-73	-83	-83	N/A
6/30/2024	95	-106	-114	-114	N/A
3/31/2024	55	-157	-128	-128	N/A
12/31/2023	28	-160	-129	-129	N/A
9/30/2023	9	-159	-116	-116	N/A
6/30/2023	1	-143	-85	-84	N/A
3/31/2023	N/A	-142	-67	-66	N/A
12/31/2022	N/A	-137	-71	-70	N/A
9/30/2022	N/A	-132	-78	-77	N/A
6/30/2022	N/A	-134	-92	-92	N/A
3/31/2022	N/A	-90	-88	-88	N/A
12/31/2021	N/A	-77	-77	-77	N/A
9/30/2021	N/A	-66	-74	-74	N/A
6/30/2021	N/A	-56	-63	-63	N/A
3/31/2021	10	-6	-61	-61	N/A
12/31/2020	22	7	-49	-49	N/A
9/30/2020	33	16	-38	-38	N/A
6/30/2020	48	18	-35	-35	N/A
3/31/2020	55	-21	-29	-29	N/A
12/31/2019	59	-33	-38	-38	N/A
9/30/2019	69	-94	-55	-55	N/A
6/30/2019	75	-101	-68	-67	N/A
3/31/2019	86	-96	-106	-86	N/A
12/31/2018	103	-95	-103	-83	N/A
9/30/2018	117	-40	-93	-72	N/A
6/30/2018	137	-2	N/A	-55	N/A
3/31/2018	154	30	N/A	-27	N/A
12/31/2017	173	68	N/A	17	N/A
9/30/2017	182	81	N/A	38	N/A
6/30/2017	174	40	N/A	37	N/A
3/31/2017	167	-9	N/A	24	N/A
12/31/2016	150	-41	N/A	19	N/A
9/30/2016	152	28	N/A	38	N/A
6/30/2016	167	19	N/A	61	N/A
3/31/2016	177	23	N/A	79	N/A
12/31/2015	173	42	N/A	84	N/A
9/30/2015	127	-64	N/A	52	N/A
6/30/2015	87	-46	N/A	36	N/A
3/31/2015	43	-49	N/A	17	N/A
12/31/2014	15	-89	N/A	-11	N/A
9/30/2014	4	-56	N/A	-11	N/A
6/30/2014	2	-52	N/A	-15	N/A
3/31/2014	4	-65	N/A	-15	N/A
12/31/2013	4	-47	N/A	-21	N/A

애널리스트 미래 성장 예측

수입 대 저축률: AVDL 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.6% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: AVDL (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: AVDL 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: AVDL 의 수익(연간 29.1% ) US 시장( 9.1% 보다 빠르게 성장할 것으로 예상됩니다. 9.1% 연간).

고성장 수익: AVDL 의 수익(연간 29.1% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: AVDL 의 자본 수익률은 3년 내에 매우 높을 것으로 예상됩니다( 141.5 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/17 19:10
장 마감 주가	2024/12/17 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Avadel Pharmaceuticals plc 17 애널리스트 중 8 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Robin Garner Kalley	Craig-Hallum Capital Group LLC
Chase Knickerbocker	Craig-Hallum Capital Group LLC
Oren Livnat	H.C. Wainwright & Co.

Avadel Pharmaceuticals 미래 성장

Future 기준 확인 6/6

주요 정보

최근 미래 성장 업데이트

Price target increased by 8.0% to US$22.90

Consensus revenue estimates increase by 18%, EPS downgraded

Consensus EPS estimates fall by 54%, revenue upgraded

Price target increased by 7.1% to US$19.33

Consensus EPS estimates upgraded to US$1.28 loss

Price target increased by 9.8% to US$18.06

Recent updates

Avadel Pharmaceuticals plc Announces Step Down of Richard Kim as Chief Commercial Officer Effective as of December 31, 2024

The Price Is Right For Avadel Pharmaceuticals plc (NASDAQ:AVDL) Even After Diving 27%

Avadel Pharmaceuticals: Despite My Sympathies For The Company, Stock Looks Risky

Avadel Pharmaceuticals plc to Report Q3, 2024 Results on Nov 12, 2024

Avadel Pharmaceuticals and nference, Inc. Publish Real-World Data on Narcolepsy in Sleep Advances

Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy

Avadel Pharmaceuticals plc's (NASDAQ:AVDL) P/S Still Appears To Be Reasonable

Health Check: How Prudently Does Avadel Pharmaceuticals (NASDAQ:AVDL) Use Debt?

Avadel Pharmaceuticals plc Announces Publication of Restore Data Highlighting Challenges with Twice-Nightly Oxybates and Strong Patient Preference for Once-Nightly LUMRYZ Dosing (sodium Oxybate) Extended-Release Oral Suspension (CIII)

Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On

Avadel Pharmaceuticals plc Announces Publication in Clinical Therapeutics of Data Highlighting Weight Loss in People with Narcolepsy Treated with LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension

Avadel Pharmaceuticals plc to Report Q2, 2024 Results on Aug 08, 2024

Avadel Pharmaceuticals plc Announces First Patient Dosed in Phase 3 REVITALYZ Trial of LUMRYZ (sodium oxybate) Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

Avadel Pharmaceuticals plc, Annual General Meeting, Jul 30, 2024

Avadel Pharmaceuticals plc, Annual General Meeting, Jul 30, 2024

Avadel Pharmaceuticals: Inflection Point Ahead

Avadel Pharmaceuticals plc Appoints Naseem Amin to Its Board of Directors

Avadel Pharmaceuticals Shares New LUMRYZ (sodium Oxybate) for Extended-Release Oral Suspension (CIII) Data at Sleep 2024

Avadel Pharmaceuticals plc Appoints Naseem Amin to Its Board of Directors

Avadel Pharmaceuticals plc has completed a Follow-on Equity Offering.

Avadel Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $100 million.

Avadel Pharmaceuticals plc to Report Q1, 2024 Results on May 08, 2024

New major risk - Share price stability

Avadel Pharmaceuticals: A Deep Dive Into Lumryz's Once-Nightly Revolution

Price target increased by 8.0% to US$22.90

Avadel Pharmaceuticals: Robust Launch Of Lumryz And Eased Litigation Overhang

Avadel Pharmaceuticals: Strong Launch Of Lumryz With A Legal Risk Backdrop

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Weighed On By Its Debt Load?

Avadel May Continue To Outperform With Positive Launch Momentum

Avadel Pharmaceuticals plc to Report Fiscal Year 2023 Results on Feb 29, 2024

Independent Director recently sold US$1.1m worth of stock

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 18%, EPS downgraded

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for Lumryz (Sodium Oxybate) for Extended-Release Oral Suspension (Ciii) At World Sleep 2023

Is Avadel Pharmaceuticals (NASDAQ:AVDL) Using Debt Sensibly?

New minor risk - Insider selling

Consensus EPS estimates fall by 54%, revenue upgraded

Key Executive recently bought US$188k worth of stock

Avadel Pharmaceuticals plc to Report Q2, 2023 Results on Aug 09, 2023

Are Investors Undervaluing Avadel Pharmaceuticals plc (NASDAQ:AVDL) By 49%?

Price target increased by 7.1% to US$19.33

Consensus EPS estimates upgraded to US$1.28 loss

Avadel Pharmaceuticals plc Announces Publication of Study Data in Advances in Therapy Highlighting Need for Once-At-Bedtime Oxybate Dosing for Narcolepsy

Price target increased by 9.8% to US$18.06

Avadel Pharmaceuticals plc Announces U.S. Commercial Launch of LUMRYZ for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Adults Living with Narcolepsy

Avadel Pharmaceuticals plc Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023

Independent Director recently bought US$181k worth of stock

Consensus revenue estimates increase by 17%

Is There An Opportunity With Avadel Pharmaceuticals plc's (NASDAQ:AVDL) 45% Undervaluation?

Price target increased by 20% to US$15.85

Consensus revenue estimates fall by 15%

Consensus revenue estimates increase by 15%, EPS downgraded

Avadel Pharmaceuticals plc Announces Publication of Real-World Data Describing Risk of Accidental Dosing Errors with Immediate-Release Twice-Nightly Oxybate

Insufficient new directors

Price target increased to US$12.25

Independent Director recently bought US$156k worth of stock

Avadel Pharmaceuticals Presents New Real-World Data Describing Demographic Characteristics and Comorbidities of Patients with Narcolepsy at ANA 2022

Avadel Pharmaceuticals filed for 500M mixed shelf offering

Price target increased to US$10.95

Avadel Pharmaceuticals Q2 2022 Earnings Preview

Price target increased to US$10.10

Avadel Pharmaceuticals plc Announces Tentative Approval of LUMRYZ Extended-Release Oral Suspension

Avadel Pharmaceuticals (NASDAQ:AVDL) Is Carrying A Fair Bit Of Debt

Avadel Pharmaceuticals Provides Corporate Update

Avadel rises 18% as it expects tentative approval for sleep disorder drug; expects final approval by June 2023

Avadel: Further Delay, But Some Light At The End Of The Tunnel

Senior VP & CFO recently bought US$107k worth of stock

Price target decreased to US$11.30

Consensus revenue estimates fall by 15%